Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
5 Excellent Dividend Growth Stocks on Sale
by Sweta Killa
Stocks with a strong history of dividend growth year over year form a healthy portfolio with a greater scope of capital appreciation.
Intersect ENT (XENT) Reports Q3 Loss, Revenues Meet Estimates
by Zacks Equity Research
Intersect ENT (XENT) exhibits a dismal performance in the third quarter of 2019.
Haemonetics (HAE) Beats on Q2 Earnings, Raises '20 EPS View
by Zacks Equity Research
Haemonetics (HAE) delivers robust fiscal second-quarter revenues, fueled by strong performances in Plasma and Hospital segments.
Surmodics (SRDX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q4.
Bio-Rad (Bio) Q3 Earnings Beat Estimates on All-Line Growth
by Zacks Equity Research
Growing strength in many of Bio-Rad's (Bio) key product lines across major geographic regions buoys investors' optimism on the stock.
Syneos Health (SYNH) Tops Q3 Earnings Estimates, Ups EPS View
by Zacks Equity Research
Syneos Health (SYNH) exhibits robust topline performance in the third quarter, backed by strong segmental growth.
Integer Holdings (ITGR) Beats on Q3 Earnings, Revenues Miss
by Zacks Equity Research
Integer Holdings' (ITGR) Q3 earnings benefit from higher revenues and strong 2019 outlook.
Bruker (BRKR) Beats Q3 Earnings Estimates, Ups EPS Guidance
by Zacks Equity Research
Bruker (BRKR) delivers robust third-quarter revenue growth, backed by strong segmental performances.
PRA Health (PRAH) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
PRA Health (PRAH) raises 2019 EPS view after a solid third-quarter show.
AMN Healthcare (AMN) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Nurse and Allied Solutions segment drives AMN Healthcare's (AMN) third-quarter results.
Teleflex (TFX) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
We are encouraged by Teleflex's (TFX) robust improvement in Q3 revenues on balanced growth across majority of segments and all geographies.
NuVasive (NUVA) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
We are encouraged to note that NuVasive (NUVA) witnessed solid revenue growth across its U.S. Spinal Hardware business in Q3.
Amedisys (AMED) Q3 Earnings Beat Estimates, Revenues Meet
by Zacks Equity Research
Amedisys (AMED) continues to witness solid year-over-year growth in Medicare and non-Medicare revenues within Home Health.
IDEXX (IDXX) Tops Q3 Earnings Estimates, Lowers EPS View
by Zacks Equity Research
IDEXX (IDXX) impresses investors with solid third-quarter 2019 results on robust performance across all business segments.
CONMED (CNMD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
CONMED's (CNMD) Q3 earnings gain from higher revenues, solid segmental performance and margin expansion. However, high long-term debt remains a concern.
Merit Medical (MMSI) Q3 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Merit Medical's (MMSI) Q3 earnings gain from higher revenues and solid segmental performance benefit. However, contraction in gross margin remains a concern.
PerkinElmer (PKI) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
PerkinElmer's (PKI) Q3 earnings benefits from higher revenues and growth in DAS and Diagnostics segments. However, forex remains a woe.
ABIOMED (ABMD) Earnings Beat, Revenues Miss Estimates in Q2
by Zacks Equity Research
Impella's solid show in Japan drives ABIOMED's (ABMD) fiscal second-quarter results.
QIAGEN (QGEN) Beats Q3 Earnings Estimates, Cuts Revenue View
by Zacks Equity Research
We are impressed with QIAGEN's (QGEN) year-over-year growth across majority of operating segments in Q3.
Masimo (MASI) Earnings Beat Estimates in Q3, View Raised
by Zacks Equity Research
Masimo (MASI) raises its 2019 product revenue guidance.
Impressive Near-Term Outlook for Medical Instruments Industry
by Urmimala Biswas
Growing medical awareness and economic prosperity enhance the uptake of medical instruments in the emerging economies.
Chemed (CHE) Q3 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Chemed (CHE) witnesses balanced segmental growth in third-quarter 2019.
McKesson (MCK) Q2 Earnings Meet Estimates, Revenues Beat
by Zacks Equity Research
McKesson's (MCK) Q2 results gain from higher revenues and solid show by U.S. Pharmaceutical and Specialty, and Medical-Surgical Solutions.
Fresenius Medical (FMS) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
Fresenius Medical's (FMS) Q3 earnings benefit from strong segmental performance and solid 2019 EPS outlook.
Stryker (SYK) Q3 Earnings Meet Estimates, Revenues Beat
by Zacks Equity Research
Stryker's (SYK) Q3 earnings gain from higher revenues, solid segmental performance and strong organic growth across businesses benefit.